Skip to main content
BioCentury on BioBusiness
Feature Story

Cover Story: Politics, Policy & Law: Patching compassionate access

Congress might move on compassionate access; wholesale reform looks unlikely

By Steve Usdin, Washington Editor

Six months after a viral media campaign saved seven-year-old Josh Hardy's life by persuading Chimerix Inc. to work with FDA to provide access to an investigational therapy, new compassionate access policies are being debated in the halls of Congress, corporate boardrooms and academic think tanks. So far, the legislative provisions under consideration represent only incremental changes to the system.

While cable television and Twitter have long since moved on, last week Rep. Michael McCaul (R-Texas), co-chair of the congressional childhood cancer caucus, told BioCentury he is drafting compassionate access legislation that he plans to introduce in 2015.

Full Article

Today's Biotech & Pharma News

Kids, Cancer and Congress


    Interrupting Ebola

    Although different companies are pursuing antibodies, vaccines or siRNAs to fight Ebola, many researchers believe it is not a race between them but a combination of approaches that will win the day.


    Canadian accelerant

    Two Canadian venture firms and a government-funded program have launched Canada's first national health science accelerator, Accel-Rx, to reignite local VC interest in funding early stage biotechs.


    ALK7's obese functions

    Researchers have shown that inhibiting ALK7 can increase energy expenditure in fat cells and suggest the protein could be a target for obesity. Acceleron Pharma has licensed the findings and is pursuing a discovery program for ALK7 antagonists.


    This Week in Therapeutics

    Disrupting AURKA's active conformation to treat MYCN-driven cancers; inhibiting ERdj3 to treat Gaucher's disease; using noninvasive electromagnetic stimulation to improve associative memory; and more...


    This Week in Techniques

    Activity-directed synthesis of bioactive scaffolds; CRISPR-Cas9 genome editing for latent viral infections; nanoparticles encoding the AEG1 promoter for prostate cancer imaging; and more...

Subscribe Now
Free Trial